Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia.

Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL; PREVENT III Investigators.

J Vasc Surg. 2006 Nov;44(5):977-83; discussion 983-4.

2.

Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.

Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL.

Vasc Endovascular Surg. 2005 Jan-Feb;39(1):15-23.

5.

Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer.

Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL.

Cancer Res. 1998 Mar 15;58(6):1159-64.

6.

Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.

Webster NJ, Kong Y, Sharma P, Haas M, Sukumar S, Seely BL.

Biochem Mol Med. 1997 Dec;62(2):139-50.

PMID:
9441865
7.

Intrapulmonary drug delivery of salmon calcitonin.

Deftos LJ, Nolan JJ, Seely BL, Clopton PL, Cote GJ, Whitham CL, Florek LJ, Christensen TA, Hill MR.

Calcif Tissue Int. 1997 Oct;61(4):345-7.

PMID:
9312206
8.

Protein tyrosine phosphatase 1B interacts with the activated insulin receptor.

Seely BL, Staubs PA, Reichart DR, Berhanu P, Milarski KL, Saltiel AR, Kusari J, Olefsky JM.

Diabetes. 1996 Oct;45(10):1379-85.

PMID:
8826975
9.

Hormonal and genetic analysis of a patient with congenital adrenal hyperplasia.

Summers RH, Herold DA, Seely BL.

Clin Chem. 1996 Sep;42(9):1483-7.

10.
11.

Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein.

Seely BL, Reichart DR, Staubs PA, Jhun BH, Hsu D, Maegawa H, Milarski KL, Saltiel AR, Olefsky JM.

J Biol Chem. 1995 Aug 11;270(32):19151-7.

12.

A functional assessment of insulin/insulin-like growth factor-I hybrid receptors.

Seely BL, Reichart DR, Takata Y, Yip C, Olefsky JM.

Endocrinology. 1995 Apr;136(4):1635-41.

PMID:
7895674
13.

Localization of the insulin receptor binding sites for the SH2 domain proteins p85, Syp, and GAP.

Staubs PA, Reichart DR, Saltiel AR, Milarski KL, Maegawa H, Berhanu P, Olefsky JM, Seely BL.

J Biol Chem. 1994 Nov 4;269(44):27186-92.

14.

Microinjection of the SH2 domain of the 85-kilodalton subunit of phosphatidylinositol 3-kinase inhibits insulin-induced DNA synthesis and c-fos expression.

Jhun BH, Rose DW, Seely BL, Rameh L, Cantley L, Saltiel AR, Olefsky JM.

Mol Cell Biol. 1994 Nov;14(11):7466-75.

15.

Diagnosis and management of pituitary tumors.

Seely BL.

Med Sect Proc. 1994:167-78. Review. No abstract available.

PMID:
7659709
16.

Stimulation of DNA synthesis and c-fos expression in corneal endothelium by insulin or insulin-like growth factor-I.

Feldman ST, Gately D, Seely BL, Schonthal A, Feramisco JR.

Invest Ophthalmol Vis Sci. 1993 May;34(6):2105-11.

PMID:
8491561
17.

Tyrosine kinase-defective insulin receptors undergo insulin-induced microaggregation but do not concentrate in coated pits.

Smith RM, Seely BL, Shah N, Olefsky JM, Jarett L.

J Biol Chem. 1991 Sep 15;266(26):17522-30.

18.

Localized chromosomal mosaicism as a cause of dysmorphic development.

Seely JR, Seely BL, Bley R Jr, Altmiller CJ.

Am J Hum Genet. 1984 Jul;36(4):899-903.

Supplemental Content

Loading ...
Support Center